Exact Mass: 519.2528694
Exact Mass Matches: 519.2528694
Found 500 metabolites which its exact mass value is equals to given mass value 519.2528694
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ala Phe Pro Trp
C28H33N5O5 (519.2481568000001)
Ala Phe Trp Pro
C28H33N5O5 (519.2481568000001)
Ala His His Arg
Ala His Arg His
Ala Ile Met Trp
Ala Ile Trp Met
Ala Leu Met Trp
Ala Leu Trp Met
Ala Met Ile Trp
Ala Met Leu Trp
Ala Met Trp Ile
Ala Met Trp Leu
Ala Pro Phe Trp
C28H33N5O5 (519.2481568000001)
Ala Pro Trp Phe
C28H33N5O5 (519.2481568000001)
Ala Arg His His
Ala Trp Phe Pro
C28H33N5O5 (519.2481568000001)
Ala Trp Ile Met
Ala Trp Leu Met
Ala Trp Met Ile
Ala Trp Met Leu
Ala Trp Pro Phe
C28H33N5O5 (519.2481568000001)
Cys Glu Ile Arg
Cys Glu Leu Arg
Cys Glu Arg Ile
Cys Glu Arg Leu
Cys Ile Glu Arg
Cys Ile Arg Glu
Cys Ile Val Trp
Cys Ile Trp Val
Cys Lys Asn Arg
Cys Lys Arg Asn
Cys Leu Glu Arg
Cys Leu Arg Glu
Cys Leu Val Trp
Cys Leu Trp Val
Cys Asn Lys Arg
Cys Asn Arg Lys
Cys Arg Glu Ile
Cys Arg Glu Leu
Cys Arg Ile Glu
Cys Arg Lys Asn
Cys Arg Leu Glu
Cys Arg Asn Lys
Cys Val Ile Trp
Cys Val Leu Trp
Cys Val Trp Ile
Cys Val Trp Leu
Cys Trp Ile Val
Cys Trp Leu Val
Cys Trp Val Ile
Cys Trp Val Leu
Asp Met Arg Val
Asp Met Val Arg
Asp Arg Met Val
Asp Arg Val Met
Asp Val Met Arg
Asp Val Arg Met
Glu Cys Ile Arg
Glu Cys Leu Arg
Glu Cys Arg Ile
Glu Cys Arg Leu
Glu Phe Lys Pro
Glu Phe Pro Lys
Glu Ile Cys Arg
Glu Ile Lys Met
Glu Ile Met Gln
Glu Ile Gln Met
Glu Ile Arg Cys
Glu Lys Phe Pro
Glu Lys Pro Phe
Glu Leu Cys Arg
Glu Leu Met Gln
Glu Leu Gln Met
Glu Leu Arg Cys
Glu Met Ile Gln
Glu Met Leu Gln
Glu Met Gln Ile
Glu Met Gln Leu
Glu Pro Phe Lys
Glu Pro Lys Phe
Glu Gln Ile Met
Glu Gln Leu Met
Glu Gln Met Ile
Glu Gln Met Leu
Glu Arg Cys Ile
Glu Arg Cys Leu
Glu Arg Ile Cys
Glu Arg Leu Cys
Phe Ala Pro Trp
C28H33N5O5 (519.2481568000001)
Phe Ala Trp Pro
C28H33N5O5 (519.2481568000001)
Phe Glu Lys Pro
Phe Glu Pro Lys
Phe Lys Glu Pro
Phe Lys Pro Glu
Phe Pro Ala Trp
C28H33N5O5 (519.2481568000001)
Phe Pro Glu Lys
Phe Pro Lys Glu
Phe Pro Trp Ala
C28H33N5O5 (519.2481568000001)
Phe Trp Ala Pro
C28H33N5O5 (519.2481568000001)
Phe Trp Pro Ala
C28H33N5O5 (519.2481568000001)
His Ala His Arg
His Ala Arg His
His His Ala Arg
His His Ile Asn
His His Leu Asn
His His Asn Ile
His His Asn Leu
His His Gln Val
His His Arg Ala
His His Val Gln
His Ile His Asn
His Ile Asn His
His Leu His Asn
His Leu Asn His
His Asn His Ile
His Asn His Leu
His Asn Ile His
His Asn Leu His
His Gln His Val
His Gln Val His
His Arg Ala His
His Arg His Ala
His Val His Gln
His Val Gln His
Ile Ala Met Trp
Ile Ala Trp Met
Ile Cys Glu Arg
Ile Cys Arg Glu
Ile Cys Val Trp
Ile Cys Trp Val
Ile Glu Cys Arg
Ile Glu Met Gln
Ile Glu Gln Met
Ile Glu Arg Cys
Ile His His Asn
Ile His Asn His
Ile Met Ala Trp
Ile Met Glu Gln
Ile Met Gln Glu
Ile Met Trp Ala
Ile Asn His His
Ile Pro Gln Tyr
Ile Pro Tyr Gln
Ile Gln Glu Met
Ile Gln Met Glu
Ile Gln Pro Tyr
Ile Gln Tyr Pro
Ile Arg Cys Glu
Ile Arg Glu Cys
Ile Thr Thr Trp
Ile Thr Trp Thr
Ile Val Cys Trp
Ile Val Trp Cys
Ile Trp Ala Met
Ile Trp Cys Val
Ile Trp Met Ala
Ile Trp Thr Thr
Ile Trp Val Cys
Ile Tyr Pro Gln
Ile Tyr Gln Pro
Lys Cys Asn Arg
Lys Cys Arg Asn
Lys Glu Phe Pro
Lys Glu Pro Phe
Lys Phe Glu Pro
Lys Phe Pro Glu
Lys Met Asn Gln
Lys Met Gln Asn
Lys Asn Cys Arg
Lys Asn Met Gln
Lys Asn Gln Met
Lys Asn Arg Cys
Lys Pro Glu Phe
Lys Pro Phe Glu
Lys Gln Met Asn
Lys Gln Asn Met
Lys Arg Cys Asn
Lys Arg Asn Cys
Leu Ala Met Trp
Leu Ala Trp Met
Leu Cys Glu Arg
Leu Cys Arg Glu
Leu Cys Val Trp
Leu Cys Trp Val
Leu Glu Cys Arg
Leu Glu Met Gln
Leu Glu Gln Met
Leu Glu Arg Cys
Leu His His Asn
Leu His Asn His
Leu Met Ala Trp
Leu Met Glu Gln
Leu Met Lys Glu
Leu Met Gln Glu
Leu Met Trp Ala
Leu Asn His His
Leu Pro Gln Tyr
Leu Pro Tyr Gln
Leu Gln Glu Met
Leu Gln Met Glu
Leu Gln Pro Tyr
Leu Gln Tyr Pro
Leu Arg Cys Glu
Leu Arg Glu Cys
Leu Thr Thr Trp
Leu Thr Trp Thr
Leu Val Cys Trp
Leu Val Trp Cys
Leu Trp Ala Met
Leu Trp Cys Val
Leu Trp Met Ala
Leu Trp Thr Thr
Leu Trp Val Cys
Leu Tyr Pro Gln
Leu Tyr Gln Pro
Met Ala Ile Trp
Met Ala Leu Trp
Met Ala Trp Ile
Met Ala Trp Leu
Met Asp Arg Val
Met Asp Val Arg
Met Glu Ile Lys
Met Glu Ile Gln
Met Glu Lys Ile
Met Glu Leu Lys
Met Glu Leu Gln
Met Glu Gln Ile
Met Glu Gln Leu
Met Ile Ala Trp
Met Ile Glu Lys
Met Ile Glu Gln
Met Ile Gln Glu
Met Ile Trp Ala
Met Lys Asn Gln
Met Lys Gln Asn
Met Leu Ala Trp
Met Leu Glu Gln
Met Leu Gln Glu
Met Leu Trp Ala
Met Asn Lys Gln
Met Asn Gln Lys
Met Gln Glu Ile
Met Gln Glu Leu
Met Gln Ile Glu
Met Gln Lys Asn
Met Gln Leu Glu
Met Gln Asn Lys
Met Arg Asp Val
Met Arg Val Asp
Met Val Asp Arg
Met Val Arg Asp
Met Trp Ala Ile
Met Trp Ala Leu
Met Trp Ile Ala
Met Trp Leu Ala
Asn Cys Lys Arg
Asn Cys Arg Lys
Asn His His Ile
Asn His His Leu
Asn His Ile His
Asn His Leu His
Asn Ile His His
Asn Lys Cys Arg
Asn Lys Met Gln
Asn Lys Gln Met
Asn Lys Arg Cys
Asn Leu His His
Asn Met Lys Gln
Asn Met Gln Lys
Asn Gln Lys Met
Asn Gln Met Lys
Asn Arg Cys Lys
Asn Arg Lys Cys
Pro Ala Phe Trp
C28H33N5O5 (519.2481568000001)
Pro Ala Trp Phe
C28H33N5O5 (519.2481568000001)
Pro Glu Phe Lys
Pro Glu Lys Phe
Pro Phe Ala Trp
C28H33N5O5 (519.2481568000001)
Pro Phe Glu Lys
Pro Phe Lys Glu
Pro Phe Trp Ala
C28H33N5O5 (519.2481568000001)
Pro Ile Gln Tyr
Pro Ile Tyr Gln
Pro Lys Glu Phe
Pro Lys Phe Glu
Pro Leu Gln Tyr
Pro Leu Tyr Gln
Pro Gln Ile Tyr
Pro Gln Leu Tyr
Pro Gln Tyr Ile
Pro Gln Tyr Leu
Pro Trp Ala Phe
C28H33N5O5 (519.2481568000001)
Pro Trp Phe Ala
C28H33N5O5 (519.2481568000001)
Pro Tyr Ile Gln
Pro Tyr Leu Gln
Pro Tyr Gln Ile
Pro Tyr Gln Leu
Gln Glu Ile Met
Gln Glu Leu Met
Gln Glu Met Ile
Gln Glu Met Leu
Gln His His Val
Gln His Val His
Gln Ile Glu Met
Gln Ile Met Glu
Gln Ile Pro Tyr
Gln Ile Tyr Pro
Gln Lys Met Asn
Gln Lys Asn Met
Gln Leu Glu Met
Gln Leu Met Glu
Gln Leu Pro Tyr
Gln Leu Tyr Pro
Gln Met Glu Ile
Gln Met Glu Leu
Gln Met Ile Glu
Gln Met Lys Asn
Gln Met Leu Glu
Gln Met Asn Lys
Gln Asn Lys Met
Gln Asn Met Lys
Gln Pro Ile Tyr
Gln Pro Leu Tyr
Gln Pro Tyr Ile
Gln Pro Tyr Leu
Gln Val His His
Gln Tyr Ile Pro
Gln Tyr Leu Pro
Gln Tyr Pro Ile
Gln Tyr Pro Leu
Arg Ala His His
Arg Cys Glu Ile
Arg Cys Glu Leu
Arg Cys Ile Glu
Arg Cys Lys Asn
Arg Cys Leu Glu
Arg Cys Asn Lys
Arg Asp Met Val
Arg Asp Val Met
Arg Glu Cys Ile
Arg Glu Cys Leu
Arg Glu Ile Cys
Arg Glu Leu Cys
Arg His Ala His
Arg His His Ala
Arg Ile Cys Glu
Arg Ile Glu Cys
Arg Lys Cys Asn
Arg Lys Asn Cys
Arg Leu Cys Glu
Arg Leu Glu Cys
Arg Met Asp Val
Arg Met Val Asp
Arg Asn Cys Lys
Arg Asn Lys Cys
Arg Val Asp Met
Arg Val Met Asp
Thr Ile Thr Trp
Thr Ile Trp Thr
Thr Leu Thr Trp
Thr Leu Trp Thr
Thr Thr Ile Trp
Thr Thr Leu Trp
Thr Thr Trp Ile
Thr Thr Trp Leu
Thr Trp Ile Thr
Thr Trp Leu Thr
Thr Trp Thr Ile
Thr Trp Thr Leu
Val Cys Ile Trp
Val Cys Leu Trp
Val Cys Trp Ile
Val Cys Trp Leu
Val Asp Met Arg
Val Asp Arg Met
Val His His Gln
Val His Gln His
Val Ile Cys Trp
Val Ile Trp Cys
Val Leu Cys Trp
Val Leu Trp Cys
Val Met Asp Arg
Val Met Arg Asp
Val Gln His His
Val Arg Asp Met
Val Arg Met Asp
Val Trp Cys Ile
Val Trp Cys Leu
Val Trp Ile Cys
Val Trp Leu Cys
Trp Ala Phe Pro
C28H33N5O5 (519.2481568000001)
Trp Ala Ile Met
Trp Ala Leu Met
Trp Ala Met Ile
Trp Ala Met Leu
Trp Ala Pro Phe
C28H33N5O5 (519.2481568000001)
Trp Cys Ile Val
Trp Cys Leu Val
Trp Cys Val Ile
Trp Cys Val Leu
Trp Phe Ala Pro
C28H33N5O5 (519.2481568000001)
Trp Phe Pro Ala
C28H33N5O5 (519.2481568000001)
Trp Ile Ala Met
Trp Ile Cys Val
Trp Ile Met Ala
Trp Ile Thr Thr
Trp Ile Val Cys
Trp Leu Ala Met
Trp Leu Cys Val
Trp Leu Met Ala
Trp Leu Thr Thr
Trp Leu Val Cys
Trp Met Ala Ile
Trp Met Ala Leu
Trp Met Ile Ala
Trp Met Leu Ala
Trp Pro Ala Phe
C28H33N5O5 (519.2481568000001)
Trp Pro Phe Ala
C28H33N5O5 (519.2481568000001)
Trp Thr Ile Thr
Trp Thr Leu Thr
Trp Thr Thr Ile
Trp Thr Thr Leu
Trp Val Cys Ile
Trp Val Cys Leu
Trp Val Ile Cys
Trp Val Leu Cys
Tyr Ile Pro Gln
Tyr Ile Gln Pro
Tyr Leu Pro Gln
Tyr Leu Gln Pro
Tyr Pro Ile Gln
Tyr Pro Leu Gln
Tyr Pro Gln Ile
Tyr Pro Gln Leu
Tyr Gln Ile Pro
Tyr Gln Leu Pro
Tyr Gln Pro Ile
Tyr Gln Pro Leu
WYE-125132(WYE-132)
WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2. WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits mTORC1 and mTORC2.
1-palmitoyl-sn-glycero-3-phospho-l-serine sodium salt
Victoria blue 4r
C34H34ClN3 (519.2441114000001)
D004396 - Coloring Agents > D012394 - Rosaniline Dyes
Pefcalcitol
C78284 - Agent Affecting Integumentary System > C29708 - Anti-psoriatic Agent
(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-({(2R)-2-azaniumyl-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-14-hydroxydocosa-4,7,9,11,16,19-hexaenoate
N-[(4R,7R,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4S,7R,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4S,7S,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7S,8R)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methylimidazole-4-sulfonamide
N-[(4S,7S,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[[(2S,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4R,7S,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(4R,7R,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[[(2S,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide
N-[[(2R,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[[(2S,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-methyl-4-imidazolesulfonamide
N-[(4S,7R,8S)-5-[(2,5-difluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
3-(4-fluorophenyl)-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
(4Z,7Z,16S,17R,19Z)-16-({(2R)-2-azaniumyl-3-[(carboxylatomethyl)amino]-3-oxopropyl}sulfanyl)-17-hydroxydocosa-4,7,10,12,14,19-hexaenoate
(3S)-1-[2-[2,2,2-tris(4-methoxyphenyl)ethoxy]ethyl]-3-piperidinecarboxylic acid
2-amino-3-[hydroxy-[2-hydroxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxypropanoic acid
(13R)-glycinylcystein-S-yl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate(1-)
A docosanoid anion obtained by deprotonation of the two carboxy groups and protonation of the glutamyl alpha-amino group of (13R)-S-cysteinylglycinyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid; major species at pH 7.3.
16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoate(1-)
A docosanoid anion obtained by deprotonation of the two carboxy groups and protonation of the alpha-amino group of 16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid; major species at pH 7.3.
KT185
C32H33N5O2 (519.2634118000001)
KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells[1].